Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer

The epidermal growth factor receptor (EGFR) and cyclooxygenase-2(COX-2) play a critical role in disease progression, relapse and therapeutic resistance of advanced prostate cancer (PCa). In this paper, we evaluated, for the first time, the therapeutic benefit of blocking EGRF and/or COX-2 (using gef...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jianzhong, Wu, Hongfei, Shi, Hui, Pan, Wei, Yu, Hongbo, Zhu, Jiageng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796533/
https://www.ncbi.nlm.nih.gov/pubmed/24155892
http://dx.doi.org/10.1371/journal.pone.0076169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796533/
https://www.ncbi.nlm.nih.gov/pubmed/24155892
http://dx.doi.org/10.1371/journal.pone.0076169

Ejemplares similares